跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Madopar HBS - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Madopar HBS
Approved
STANDARD
Madopar HBS
Delpharm Milano S.r.L
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
463532222eb6e2e9
Company
Delpharm Milano S.r.L
Type
Standard
Approval Details
Approval Id
463532222eb6e2e9
Drug Approval Philippines Name
Madopar HBS
Product Name
Madopar HBS
Registration Number
DR-XY40316
Brand Name
Madopar HBS
Generic Name
Levodopa + Benserazide (As Hydrochloride)
Dosage Form
Tablet
Dosage Strength
100 mg/ 25 mg
Manufacturer
Delpharm Milano S.r.L
Importer
Roche (Philippines), Inc.
Distributor
Roche (Philippines), Inc.
Issuance Date
25 August 2022
Expiry Date
25 August 2027
Pharmacologic Category
Antiparkinsonism (Dopaminergic)
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
463532222eb6e2e9
Type
Standard
Back to Philippines FDA Approvals